Postapproval studies of drugs initially approved by the FDA on the basis of limited evidence: Systematic review

Alison M. Pease, Harlan M. Krumholz, Nicholas S. Downing, Jenerius A. Aminawung, Nilay D Shah, Joseph S. Ross

Research output: Contribution to journalReview article

50 Citations (Scopus)

Abstract

Objective To characterize the prospective controlled clinical studies for all novel drugs that were initially approved by the Food and Drug Administration on the basis of limited evidence. Design Systematic review. Data sources Drugs@FDA database and PubMed. Study inclusion All prospective controlled clinical studies published after approval for all novel drugs initially approved by the FDA between 2005 and 2012 on the basis of a single pivotal trial, pivotal trials that used surrogate markers of disease as primary endpoints, or both. Results Between 2005 and 2012 the FDA approved 117 novel drugs for 123 indications on the basis of a single pivotal trial, pivotal trials that used surrogate markers of disease, or both (single surrogate trials). We identified 758 published controlled studies over a median of 5.5 years (interquartile range 3.4-8.2) after approval, most of which (554 of 758; 73.1%) were studies for indications approved on the basis of surrogate markers of disease. Most postapproval studies used active comparators - 67 of 77 (87.0%) indications approved on the basis of single pivotal trials, 365 of 554 (65.9%) approvals based on surrogate marker trials, and 100 of 127 (78.7%) approvals based on single surrogate trials - and examined surrogate markers of efficacy as primary endpoints - 51 of 77 (66.2%), 512 of 554 (92.4%), and 110 of 127 (86.6%), respectively. Overall, no postapproval studies were identified for 43 of the 123 (35.0%) approved indications. The median total number of postapproval studies identified was 1 (interquartile range 0-2) for indications approved on the basis of a single pivotal trial, 3 (1-8) for indications approved on the basis of pivotal trials that used surrogate markers of disease as primary endpoints, and 1 (0-2) for single surrogate trial approvals, and the median aggregate number of patients enrolled in postapproval studies was 90 (0-509), 533 (122-3633), and 38 (0-666), respectively. The proportion of approved indications with one or more randomized, controlled, double blind study using a clinical outcome for the primary endpoint that was published after approval and showed superior efficacy was 18.2% (6 of 33), 2.0% (1 of 49), and 4.9% (2 of 41), respectively. Conclusions The quantity and quality of postapproval clinical evidence varied substantially for novel drugs first approved by the FDA on the basis of limited evidence, with few controlled studies published after approval that confirmed efficacy using clinical outcomes for the original FDA approved indication.

Original languageEnglish (US)
Article numberj1680
JournalBMJ (Online)
Volume357
DOIs
StatePublished - 2017

Fingerprint

Biomarkers
Pharmaceutical Preparations
Pharmaceutical Databases
Information Storage and Retrieval
United States Food and Drug Administration
Double-Blind Method
PubMed
Clinical Studies

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Postapproval studies of drugs initially approved by the FDA on the basis of limited evidence : Systematic review. / Pease, Alison M.; Krumholz, Harlan M.; Downing, Nicholas S.; Aminawung, Jenerius A.; Shah, Nilay D; Ross, Joseph S.

In: BMJ (Online), Vol. 357, j1680, 2017.

Research output: Contribution to journalReview article

Pease, Alison M. ; Krumholz, Harlan M. ; Downing, Nicholas S. ; Aminawung, Jenerius A. ; Shah, Nilay D ; Ross, Joseph S. / Postapproval studies of drugs initially approved by the FDA on the basis of limited evidence : Systematic review. In: BMJ (Online). 2017 ; Vol. 357.
@article{01641140892144b79f979babd6682599,
title = "Postapproval studies of drugs initially approved by the FDA on the basis of limited evidence: Systematic review",
abstract = "Objective To characterize the prospective controlled clinical studies for all novel drugs that were initially approved by the Food and Drug Administration on the basis of limited evidence. Design Systematic review. Data sources Drugs@FDA database and PubMed. Study inclusion All prospective controlled clinical studies published after approval for all novel drugs initially approved by the FDA between 2005 and 2012 on the basis of a single pivotal trial, pivotal trials that used surrogate markers of disease as primary endpoints, or both. Results Between 2005 and 2012 the FDA approved 117 novel drugs for 123 indications on the basis of a single pivotal trial, pivotal trials that used surrogate markers of disease, or both (single surrogate trials). We identified 758 published controlled studies over a median of 5.5 years (interquartile range 3.4-8.2) after approval, most of which (554 of 758; 73.1{\%}) were studies for indications approved on the basis of surrogate markers of disease. Most postapproval studies used active comparators - 67 of 77 (87.0{\%}) indications approved on the basis of single pivotal trials, 365 of 554 (65.9{\%}) approvals based on surrogate marker trials, and 100 of 127 (78.7{\%}) approvals based on single surrogate trials - and examined surrogate markers of efficacy as primary endpoints - 51 of 77 (66.2{\%}), 512 of 554 (92.4{\%}), and 110 of 127 (86.6{\%}), respectively. Overall, no postapproval studies were identified for 43 of the 123 (35.0{\%}) approved indications. The median total number of postapproval studies identified was 1 (interquartile range 0-2) for indications approved on the basis of a single pivotal trial, 3 (1-8) for indications approved on the basis of pivotal trials that used surrogate markers of disease as primary endpoints, and 1 (0-2) for single surrogate trial approvals, and the median aggregate number of patients enrolled in postapproval studies was 90 (0-509), 533 (122-3633), and 38 (0-666), respectively. The proportion of approved indications with one or more randomized, controlled, double blind study using a clinical outcome for the primary endpoint that was published after approval and showed superior efficacy was 18.2{\%} (6 of 33), 2.0{\%} (1 of 49), and 4.9{\%} (2 of 41), respectively. Conclusions The quantity and quality of postapproval clinical evidence varied substantially for novel drugs first approved by the FDA on the basis of limited evidence, with few controlled studies published after approval that confirmed efficacy using clinical outcomes for the original FDA approved indication.",
author = "Pease, {Alison M.} and Krumholz, {Harlan M.} and Downing, {Nicholas S.} and Aminawung, {Jenerius A.} and Shah, {Nilay D} and Ross, {Joseph S.}",
year = "2017",
doi = "10.1136/bmj.j1680",
language = "English (US)",
volume = "357",
journal = "The BMJ",
issn = "0959-8146",
publisher = "BMJ Publishing Group",

}

TY - JOUR

T1 - Postapproval studies of drugs initially approved by the FDA on the basis of limited evidence

T2 - Systematic review

AU - Pease, Alison M.

AU - Krumholz, Harlan M.

AU - Downing, Nicholas S.

AU - Aminawung, Jenerius A.

AU - Shah, Nilay D

AU - Ross, Joseph S.

PY - 2017

Y1 - 2017

N2 - Objective To characterize the prospective controlled clinical studies for all novel drugs that were initially approved by the Food and Drug Administration on the basis of limited evidence. Design Systematic review. Data sources Drugs@FDA database and PubMed. Study inclusion All prospective controlled clinical studies published after approval for all novel drugs initially approved by the FDA between 2005 and 2012 on the basis of a single pivotal trial, pivotal trials that used surrogate markers of disease as primary endpoints, or both. Results Between 2005 and 2012 the FDA approved 117 novel drugs for 123 indications on the basis of a single pivotal trial, pivotal trials that used surrogate markers of disease, or both (single surrogate trials). We identified 758 published controlled studies over a median of 5.5 years (interquartile range 3.4-8.2) after approval, most of which (554 of 758; 73.1%) were studies for indications approved on the basis of surrogate markers of disease. Most postapproval studies used active comparators - 67 of 77 (87.0%) indications approved on the basis of single pivotal trials, 365 of 554 (65.9%) approvals based on surrogate marker trials, and 100 of 127 (78.7%) approvals based on single surrogate trials - and examined surrogate markers of efficacy as primary endpoints - 51 of 77 (66.2%), 512 of 554 (92.4%), and 110 of 127 (86.6%), respectively. Overall, no postapproval studies were identified for 43 of the 123 (35.0%) approved indications. The median total number of postapproval studies identified was 1 (interquartile range 0-2) for indications approved on the basis of a single pivotal trial, 3 (1-8) for indications approved on the basis of pivotal trials that used surrogate markers of disease as primary endpoints, and 1 (0-2) for single surrogate trial approvals, and the median aggregate number of patients enrolled in postapproval studies was 90 (0-509), 533 (122-3633), and 38 (0-666), respectively. The proportion of approved indications with one or more randomized, controlled, double blind study using a clinical outcome for the primary endpoint that was published after approval and showed superior efficacy was 18.2% (6 of 33), 2.0% (1 of 49), and 4.9% (2 of 41), respectively. Conclusions The quantity and quality of postapproval clinical evidence varied substantially for novel drugs first approved by the FDA on the basis of limited evidence, with few controlled studies published after approval that confirmed efficacy using clinical outcomes for the original FDA approved indication.

AB - Objective To characterize the prospective controlled clinical studies for all novel drugs that were initially approved by the Food and Drug Administration on the basis of limited evidence. Design Systematic review. Data sources Drugs@FDA database and PubMed. Study inclusion All prospective controlled clinical studies published after approval for all novel drugs initially approved by the FDA between 2005 and 2012 on the basis of a single pivotal trial, pivotal trials that used surrogate markers of disease as primary endpoints, or both. Results Between 2005 and 2012 the FDA approved 117 novel drugs for 123 indications on the basis of a single pivotal trial, pivotal trials that used surrogate markers of disease, or both (single surrogate trials). We identified 758 published controlled studies over a median of 5.5 years (interquartile range 3.4-8.2) after approval, most of which (554 of 758; 73.1%) were studies for indications approved on the basis of surrogate markers of disease. Most postapproval studies used active comparators - 67 of 77 (87.0%) indications approved on the basis of single pivotal trials, 365 of 554 (65.9%) approvals based on surrogate marker trials, and 100 of 127 (78.7%) approvals based on single surrogate trials - and examined surrogate markers of efficacy as primary endpoints - 51 of 77 (66.2%), 512 of 554 (92.4%), and 110 of 127 (86.6%), respectively. Overall, no postapproval studies were identified for 43 of the 123 (35.0%) approved indications. The median total number of postapproval studies identified was 1 (interquartile range 0-2) for indications approved on the basis of a single pivotal trial, 3 (1-8) for indications approved on the basis of pivotal trials that used surrogate markers of disease as primary endpoints, and 1 (0-2) for single surrogate trial approvals, and the median aggregate number of patients enrolled in postapproval studies was 90 (0-509), 533 (122-3633), and 38 (0-666), respectively. The proportion of approved indications with one or more randomized, controlled, double blind study using a clinical outcome for the primary endpoint that was published after approval and showed superior efficacy was 18.2% (6 of 33), 2.0% (1 of 49), and 4.9% (2 of 41), respectively. Conclusions The quantity and quality of postapproval clinical evidence varied substantially for novel drugs first approved by the FDA on the basis of limited evidence, with few controlled studies published after approval that confirmed efficacy using clinical outcomes for the original FDA approved indication.

UR - http://www.scopus.com/inward/record.url?scp=85019080254&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019080254&partnerID=8YFLogxK

U2 - 10.1136/bmj.j1680

DO - 10.1136/bmj.j1680

M3 - Review article

C2 - 28468750

AN - SCOPUS:85019080254

VL - 357

JO - The BMJ

JF - The BMJ

SN - 0959-8146

M1 - j1680

ER -